Sun Pharmaceutical Industries is currently trading at Rs. 420.00, up by 6.40 points or 1.55% from its previous closing of Rs. 413.60 on the BSE.
The scrip opened at Rs. 416.00 and has touched a high and low of Rs. 428.05 and Rs. 413.05 respectively. So far 1643523 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 678.80 on 06-Sep-2018 and a 52 week low of Rs. 402.10 on 05-Dec-2018.
Last one week high and low of the scrip stood at Rs. 493.90 and Rs. 402.10 respectively. The current market cap of the company is Rs. 101155.68 crore.
The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 33.31% and 12.31% respectively.
Sun Pharmaceutical Industries including its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.
The generic version is therapeutic equivalent to Organon’s Ganirelix Acetate Injection, 250 mcg/0.5 mL. As per IQVIA, Ganirelix Acetate Injection, 250 mcg/0.5 mL had annual sales of approximately $67 million in the US for the 12 months ended September 2018. The commercialization of this product in the US market is expected in Q4FY19.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |